Anti-TNF and thiopurine therapy in pregnant IBD patients does not significantly alter a panel of B-cell and T-cell subsets in 1-year-old infants

Objectives: Infants exposed to combination therapy with anti‐tumor necrosis factor (anti‐TNF) agents and thiopurines may exhibit increased infections at 1 year of age compared to unexposed infants. We hypothesized that this increased risk of infection is due to abnormal development of the newborn immune system. Methods: We immunophenotyped B‐cell and T‐cell subsets using multiparameter flow cytometry in 1‐year‐old infants whose mothers were exposed to therapeutic agents for IBD. We analyzed samples from infants exposed to infliximab (IFX) or adalimumab (ADA) monotherapy (IFX/ADA, n = 11), certolizumab pegol (CZP) monotherapy (CZP, n = 4), IFX or ADA plus thiopurine combination therapy (IFX/ADA + IM, n = 4), and CZP plus thiopurine combination therapy (CZP + IM, n = 2). Results: Percentages of B cells, CD4+ T helper cells, T regulatory cells (Tregs), and CD8+ cytotoxic T cells, were similar among the groups. Infants exposed to combination therapy (IFX/ADA + IM) exhibited trends toward fewer CD27+ B cells, switched memory B cells, plasmablasts, interferon gamma (IFN&ggr;)‐producing CD4+ and CD8+ T cells, and CCR5+CD4+ T cells, but these did not reach statistical significance. Conclusions: Multiparameter immunophenotyping of major B‐cell and T‐cell subsets suggests that the adaptive newborn immune system develops largely unaltered after exposure to combination therapy as compared to anti‐TNF monotherapy.

• Publication year

  2018

• Venue

  Clinical and Translational Gastroenterology

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41424-018-0018-3PMID 29618720PMCID 5886978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pregnancy Outcomes After Exposure to Certolizumab Pegol

  2018cited by this paper
• Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines

  2018cited by this paper
• Inadequate Gestational Weight Gain Predicts Adverse Pregnancy Outcomes in Mothers with Inflammatory Bowel Disease: Results from a Prospective US Pregnancy Cohort

  2017cited by this paper
• Critical Role of Myeloid-Derived Suppressor Cells in Tumor-Induced Liver Immune Suppression through Inhibition of NKT Cell Function

  2017cited by this paper
• Drug Safety and Risk of Adverse Outcomes for Pregnant Patients With Inflammatory Bowel Disease.

  2017cited by this paper
• Unique aspects of the perinatal immune system

  2017cited by this paper
• Immunological Changes in Blood of Newborns Exposed to Anti-TNF-α during Pregnancy

  2017cited by this paper
• B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis

  2017cited by this paper
• Adherence to medical treatment in relation to pregnancy, birth outcome & breastfeeding behavior among women with Crohn's disease.

  2016cited by this paper
• Use of Immunomodulators and Biologics Before, During, and After Pregnancy

  2016cited by this paper
• The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy.

  2016cited by this paper
• Mass Cytometry: Single Cells, Many Features.

  2016cited by this paper
• Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection.

  2016cited by this paper
• Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry

  2015cited by this paper
• Inflammatory Bowel Disease Increases Risk of Adverse Pregnancy Outcomes: A Meta-Analysis

  2015cited by this paper
• Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency.

  2015cited by this paper
• Tu1320 Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From Safety Surveillance

  2015cited by this paper
• Antibody-independent functions of B cells: a focus on cytokines

  2015cited by this paper
• Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease.

  2014cited by this paper
• Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD

  2014cited by this paper
• Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn’s disease

  2014cited by this paper
• Birth Outcomes in Women with Inflammatory Bowel Disease: Effects of Disease Activity and Drug Exposure

  2014cited by this paper
• Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohn's disease.

  2014cited by this paper
• Safety of Thiopurines and Anti-TNF-α Drugs During Pregnancy in Patients With Inflammatory Bowel Disease

  2013cited by this paper
• Memory B Cells in Mouse Models

  2013cited by this paper
• Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.

  2013cited by this paper
• Combined immunodeficiency with life-threatening EBV-associated lymphoproliferative disorder in patients lacking functional CD27

  2013cited by this paper
• Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease

  2013cited by this paper
• Early Differentiated CD138highMHCII+IgG+ Plasma Cells Express CXCR3 and Localize into Inflamed Kidneys of Lupus Mice

  2013cited by this paper
• Importance of appropriate pharmaceutical management in pregnant women with ulcerative colitis

  2013cited by this paper
• 865 PIANO: A 1000 Patient Prospective Registry of Pregnancy Outcomes in Women With IBD Exposed to Immunomodulators and Biologic Therapy

  2012cited by this paper
• Regulatory T cells: mechanisms of differentiation and function.

  2012cited by this paper
• CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia.

  2012cited by this paper
• Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease.

  2011cited by this paper
• Infliximab, azathioprine, or combination therapy for Crohn's disease.

  2010cited by this paper
• Adalimumab level in breast milk of a nursing mother.

  2010cited by this paper
• Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature.

  2010cited by this paper
• Azathioprine treatment during lactation

  2008cited by this paper
• The EUROclass trial: defining subgroups in common variable immunodeficiency.

  2008cited by this paper
• Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California.

  2007cited by this paper
• CCR5 deficiency increases risk of symptomatic West Nile virus infection

  2006cited by this paper
• Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease.

  1999cited by this paper
• Characterization of tumor necrosis factor-deficient mice.

  1997cited by this paper
• Immune and inflammatory responses in TNF alpha-deficient mice: a critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response

  1996cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• Case Report and Review of the Literature: Ureteral Endometriosis

  1987cited by this paper

• Pediatric infections in the first year of life following maternal biologic exposure for autoimmune disorder treatment: A systematic review.

  2025cites this paper
• Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.

  2025cites this paper
• Global consensus statement on the management of pregnancy in inflammatory bowel disease

  2025cites this paper
• Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease

  2025cites this paper
• Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.

  2025cites this paper
• Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.

  2025cites this paper
• Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.

  2025cites this paper
• LIVE ROTAVIRUS VACCINATION APPEARS LOW-RISK IN INFANTS BORN TO MOTHERS WITH INFLAMMATORY BOWEL DISEASE ON BIOLOGICS.

  2024cites this paper
• Navigating anti-TNF therapy risks: Real-world insights on pregnancy, breastfeeding, and vaccines in IBD patients.

  2024cites this paper
• Curcumin-Encapsulated Co-ZIF-8 for Ulcerative Colitis Therapy: ROS Scavenging and Macrophage Modulation Effects

  2024cites this paper
• Expected impact of immunomodulatory agents during pregnancy: A newborn's perspective

  2023cites this paper
• Vaccines in children exposed to biological agents in utero and/or during breastfeeding: are they effective and safe?

  2023cites this paper
• The Effect of In Utero Exposure to Maternal Inflammatory Bowel Disease and Immunomodulators on Infant Immune System Development and Function

  2023cites this paper
• Exposure to medication for neurological disease in pregnancy – time to consider the long-term implications?

  2023cites this paper
• Chitosan-coated artesunate protects against ulcerative colitis via STAT6-mediated macrophage M2 polarization and intestinal barrier protection.

  2023cites this paper
• Research progress on the relationship between Paneth cells-susceptibility genes, intestinal microecology and inflammatory bowel disease

  2023cites this paper
• European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation.

  2022cites this paper
• Safety of in utero exposure to maternal IBD pharmacotherapies

  2022cites this paper
• Immune function in newborns with in-utero exposure to anti-TNFα therapy

  2022cites this paper
• Use of medications during pregnancy and breastfeeding for Crohn’s disease and ulcerative colitis

  2021cites this paper
• CANADIAN ASSOCIATION OF GASTROENTEROLOGY CLINICAL PRACTICE GUIDELINE FOR IMMUNIZATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD). PART 1: LIVE VACCINES.

  2021cites this paper
• Anti-cytokine therapy and small molecule agents for the treatment of inflammatory bowel disease

  2021cites this paper
• Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines

  2021cites this paper
• Paediatric infections in the first 3 years of life after maternal anti‐TNF treatment during pregnancy

  2020cites this paper
• Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review

  2020cites this paper
• Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease.

  2020cites this paper
• Impact of infections in autoimmune rheumatic diseases and pregnancy.

  2019cites this paper
• From mother to baby: antenatal exposure to monoclonal antibody biologics

  2019cites this paper
• Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system

  2018cites this paper
• Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab

  2018cites this paper
• The Profile of Human Milk Metabolome, Cytokines, and Antibodies in Inflammatory Bowel Diseases Versus Healthy Mothers, and Potential Impact on the Newborn

  2018cites this paper
• Inadequate Gestational Weight Gain Predicts Adverse Pregnancy Outcomes in Mothers with Inflammatory Bowel Disease: Results from a Prospective US Pregnancy Cohort

  2017cites this paper